Professor Kate Ren

All publications

Journal articles

• Harnan S, Hamilton J, Simpson E, Clowes M, Biz AN, Whyte S, Ren S, Cooper K, Ball A, Benton S , Carten R et al (2024) PP09 Fecal Immunochemical Tests For Patients With Symptoms Suggestive Of Colorectal Cancer: A Systematic Review And Multiple-Threshold Meta-Analysis. International Journal of Technology Assessment in Health Care, 40(S1), S56-S57.
• Biz AN, Stevenson M, Whyte S, Hamilton J, Ren S, Heathcote L, Simpson E, Cooper K, Clowes M, Ball A , Benton S et al (2024) OP15 Cost-Effectiveness Of Quantitative Fecal Immunochemical Tests For Detecting Suspected Colorectal Cancer In The Context Of Colonoscopy Capacity Constraints. International Journal of Technology Assessment in Health Care, 40(S1), S7-S7.
• Harnan S, Hamilton J, Simpson E, Clowes M, Biz AN, Whyte S, Ren K, Cooper K, Abulafi M, Ball A , Benton S et al (2024) MT55: Faecal immunochemical tests for patients in primary care with symptoms of colorectal cancer: systematic review and multiple-threshold meta-analysis. Value in Health, 27(12). View this article in WRRO
• Forsyth J, Wong R & Ren K (2024) SA36 Are We Making Expert Use of Experts? A Scoping Review of Expert Elicitation in Survival Extrapolation. Value in Health, 27(12), S620-S620.
• Forsyth J, Mitra S, Wong R, Srivastava T & Ren K (2024) HTA112 Can Excess Hazard Models Enhance Survival Analysis in Health Technology Assessments?. Value in Health, 27(12), S375-S375.
• Ren K & Forsyth J (2024) SA113 Enhancing Expert Elicitation in Health Technology Assessment: Practical Insights and Recommendations. Value in Health, 27(12), S636-S636.
• Grand T, Thokala P, Ren K, Regnier S, Oudin Åström D, Awad SF, Bidani A & Krismer PF (2024) EE334 Use of Disease Analogues to Inform Health-Economic Parameters for Economic Evaluations of Rare Diseases: A Case-Study of Multiple System Atrophy. Value in Health, 27(12), S120-S120.
• Combe E, Jones D, Knight H, Laskier V, Ren K, Wright T, Böing EA & Trivedi P (2024) CO131 Comparative Efficacy of Elafibranor and Seladelpar in Patients With Primary Biliary Cholangitis: A Network Meta-Analysis. Value in Health, 27(12), S39-S39.
• Wheat H, Ren K & Stevenson MD (2024) MSR61 Investigating the Use of the Difference Method for Sampling More Than Two Ordered Variables. Value in Health, 27(12), S449-S449.
• Knowles M, Kroep S & Ren K (2024) MSR213 Comparative Efficacy of Treatments in Advanced/Metastatic Pancreatic Cancer: Demonstrating the Power of Multi-Level Network Meta Regression. Value in Health, 27(12), S480-S480.
• Shah B, Challagulla S, Xu S, Williams R, Ren S, Srivastava T, Gautam R & Yang K (2024) MCL-509 Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). Clinical Lymphoma Myeloma and Leukemia, 24, S516-S517.
• Shah B, Challagulla S, Xu S, Williams R, Ren S, Srivastava T, Gautam R & Yang K (2024) Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). Clinical Lymphoma Myeloma and Leukemia, 24, S227-S227.
• Ren S, Essat M, Pandor A, Goodacre S, Ren S, Clowes M, Bima P, Toyofuku M, McLatchie R & Bossone E (2024) Diagnostic accuracy of the aortic dissection detection risk score alone or with D-dimer for acute aortic syndromes: systematic review and meta-analysis. PLOS ONE, 19(6). View this article in WRRO
• Essat M, Goodacre S, Pandor A, Ren S, Ren S & Clowes M (2024) Diagnostic Accuracy of D-Dimer for Acute Aortic Syndromes: Systematic Review and Meta-Analysis. Annals of Emergency Medicine.
• Srivastava T, Gupta A, Gautam R, Hriday K & Ren S (2024) SA46 Are We Dealing With Heterogeneity in Network Meta-Analysis Appropriately? A Review of NICE Submissions. Value in Health, 27(6), S403-S404.
• Grand TS, Ren S, Hall J, Åström DO, Regnier S & Thokala P (2024) Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review. PharmacoEconomics, 1-13.
• Ren S, Ren S, Welton NJ & Strong M (2024) Advancing unanchored simulated treatment comparisons: A novel implementation and simulation study. Research Synthesis Methods.
• Dunnewind N, Ainsworth C, Ren S & Kroep S (2023) SA80 Priors on Between-Study Heterogeneity in Bayesian Meta-Analysis Models: A Simulation Study Using Hamiltonian Monte Carlo Sampling. Value in Health, 26(12), S557-S557.
• Ren S & Ren S (2023) MSR159 A Novel Unanchored Simulated Treatment Comparison Approach for Time-to-Event Data. Value in Health, 26(12), S424-S424.
• Metry A, Pandor A, Ren S, Shippam A, Clowes M, Dark P, McMullan R & Stevenson M (2023) Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis. Health Technology Assessment, 27(14). View this article in WRRO
• Zhu D, Ren S, Mills K, Hull J & Dhariwal M (2023) Rate of complete spectacle independence with a trifocal intraocular lens: a systematic literature review and meta-analysis. Ophthalmology and Therapy, 12(2), 1157-1171.
• Duro EM, Julious SA & Ren S (2022) An investigation of the constancy of effect in Cochrane systematic reviews in context with the assumptions for noninferiority trials. BMC Medical Research Methodology, 22(1).
• Mandrik O, Fotheringham J, Ren S, Tice JA, Chapman RH, Stevenson MD, Pearson SD, Herron-Smith S, Agboola F & Thokala P (2022) The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. Clinical Journal of the American Society of Nephrology, 17(3), 385-394.
• Thokala P, Fuller GW, Goodacre S, Keating S, Herbert E, Perkins GD, Rosser A, Gunson I, Miller J, Ward M , Bradburn M et al (2021) Cost-effectiveness of out-of-hospital continuous positive airway pressure for acute respiratory failure: decision analytic modelling using data from a feasibility trial. BMC Emergency Medicine, 21. View this article in WRRO
• Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG & Chapman RH (2020) Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Effectiveness and Resource Allocation, 18. View this article in WRRO
• Hart R, Burns D, Ramaekers B, Ren S, Gladwell D, Sullivan W, Davison N, Saunders O, Sly I, Cain T & Lee D (2020) R and Shiny for cost-effectiveness analyses : why and when? A hypothetical case study. PharmacoEconomics. View this article in WRRO
• Kearns B, Stevens J, Ren S & Brennan A (2020) How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. PharmacoEconomics, 38(2), 193-204. View this article in WRRO
• Laskier V, Guy H, Fisher M, Neuman WR, Bucior I, Cohen AT & Ren S (2019) Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients : a systematic literature review and network meta-analysis. Journal of Medical Economics. View this article in WRRO
• Simpson EL, Ren S, Hock ES, Stevens JW, Binard A, Pers Y-M, Archer R, Paisley S, Stevenson MD, Herpin C & Ghabri S (2019) Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.. International Journal of Technology Assessment in Health Care. View this article in WRRO
• Ren S, Squires H, Hock E, Kaltenthaler E, Rawdin A & Alifrangis C (2018) Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
• Pennington B, Ren S, Barton S, Bacelar M & Edwards SJ (2018) Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
• Ren S, Bermejo I, Simpson E, Wong R, Scott D, Young A & Stevenson M (2018) Baricitinib for previously treated moderate or severe rheumatoid arthritis: an evidence review group perspective of a NICE single technology appraisal . PharmacoEconomics, 36, 769-778. View this article in WRRO
• Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A & Stevenson M (2018) Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 36(12), 1427-1437. View this article in WRRO
• Ren S, Oakley JE & Stevens JW (2018) Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses. Medical Decision Making, 38(4), 531-542. View this article in WRRO
• Uttley L, Bermejo I, Ren S, Martyn-St James M, Wong R, Scott DL, Young A & Stevenson M (2018) Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(9), 1063-1072. View this article in WRRO
• Ren S, Minton J, Whyte S, Latimer N & Stevenson M (2017) A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis. PharmacoEconomics. View this article in WRRO
• Sadler S, Holmes M, Ren S, Holden S, Jha S & Thokala P (2017) Cost-effectiveness of antibiotic treatment of uncomplicated urinary tract infection in women: a comparison of four antibiotics. BJGP Open, 1(3). View this article in WRRO
• Uttley L, Whyte S, Gomersall T, Ren S, Wong R, Chambers D & Tappenden P (2017) Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(7), 717-726. View this article in WRRO
• Bojke L, Manca A, Asaria M, Mahon R, Ren S & Palmer S (2017) How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. PharmacoEconomics. View this article in WRRO
• Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A & Sharples L (2017) Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making, 37(4), 377-390. View this article in WRRO
• Cooper KL, Martyn-StJames M, Kaltenthaler E, Dickinson K, Cantrell A, Ren S, Wylie K, Frodsham L & Hood C (2017) Complementary and Alternative Medicine for Management of Premature Ejaculation: A Systematic Review. Sexual Medicine, 5(1), e1-e18. View this article in WRRO
• Martyn-St James M, Cooper K, Ren S, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L & Hood C (2017) Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. European Urology Focus, 3(1), 119-129. View this article in WRRO
• Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S & Tidy J (2017) Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(1), 97-109. View this article in WRRO
• Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. PharmacoEconomics, 34(10), 1023-1038. View this article in WRRO
• Harnan S, Ren S, Gomersall T, hock , sutton A, Dhanasiri S & Kulasekararaj A (2016) Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis. Acta Haematologica, 136(1), 23-42. View this article in WRRO
• Morrell CJ, Sutcliffe P, Booth A, Stevens J, Scope A, Stevenson M, Harvey R, Bessey A, Cantrell A, Dennis C-L , Ren S et al (2016) A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. Health Technology Assessment, 20(37), 1-414. View this article in WRRO
• Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A & Hoque S (2016) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment, 20(39), 1-326. View this article in WRRO
• Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, Lobo A & Hoque S (2016) Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(3), 245-257. View this article in WRRO
• Martyn-St James M, Cooper K, Ren K, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L & Hood C (2016) Topical anaesthetics for premature ejaculation: a systematic review and meta-analysis. Sexual Health, 13(2), 114-123. View this article in WRRO
• Goodacre S, Stevens JW, Pandor A, Poku E, Ren S, Cantrell A, Bounes V, Mas A, Payen D, Petrie D , Roessler MS et al (2014) Prehospital Noninvasive Ventilation for Acute Respiratory Failure: Systematic Review, Network Meta-analysis, and Individual Patient Data Meta-analysis. Academic Emergency Medicine, 21(9), 960-970. View this article in WRRO
• Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Cantrell A & Michaels J (2014) Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins.. Br J Surg, 101(9), 1040-1052. View this article in WRRO
• Leaviss J, Hummel S, Carroll C, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M & Michaels J (2014) Clinical and cost-effectiveness of minimally invasive techniques for the treatment of varicosis: Systematic review and economic evaluation. Vasomed, 26(4), 210-211.
• Ren S & Oakley JE (2014) Assurance calculations for planning clinical trials with time-to-event outcomes. Statistics in Medicine, 33(1), 31-45. View this article in WRRO
• Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, Strong M & Cantrell A (2014) What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.. Health Technol Assess, 18(33), 1-120.
• Uttley L, Kearns B, Ren S & Stevenson M (2013) Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.. Pharmacoeconomics, 31(11), 981-990.
• Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M & Michaels J (2013) Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation.. Health Technol Assess, 17(48), i-141.
• Woods B, Kearns B, Schmitt L, Jankovic D, Rothery C, Harnan S, Hamilton J, Scope A, Ren S, Bojke L , Wilcox M et al () Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England. Applied Health Economics and Health Policy.
• Harnan S, Hamilton J, Simpson E, Clowes M, Navega Biz A, Whyte S, Ren S, Cooper K, Abulafi M, Ball A , Beton S et al () Faecal Immunochemical Tests For Patients With Symptoms Suggestive Of Colorectal Cancer: An Updated Systematic Review And Multiple-Threshold Meta-Analysis of Diagnostic Test Accuracy Studies. Colorectal Disease.
• Harnan S, Kearns B, Scope A, Schmitt L, Jankovic D, Hamilton J, Srivastava T, Hill H, Ku CC, Ren S , Rothery C et al () Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment, 1-230.
• Woods B, Schmitt L, Jankovic D, Kearns B, Scope A, Ren S, Srivastava T, Ku CC, Hamilton J, Rothery C , Bojke L et al () Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment, 1-238.
• Thokala P, Srivastava T, Smith R, Ren S, Whittington MD, Elvidge J, Wong R & Uttley L () Living Health Technology Assessment: Issues, Challenges and Opportunities. PharmacoEconomics.
• Pandor A, Thokala P, Goodacre S, Poku E, Stevens JW, Ren S, Cantrell A, Perkins GD, Ward M & Penn-Ashman J () Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technology Assessment, 19(42), 1-102. View this article in WRRO
• Leaviss J, Davis S, Ren S, Hamilton J, Scope A, Booth A, Sutton A, Parry G, Buszewicz M, Moss-Morris R & White P () Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. Health Technology Assessment, 24(46), 1-490.

Conference proceedings papers

• Goodacre S, Ren S, Essat M, Pandor A, Ren S, Clowes M, Bima P, Toyofuku M, McLatchie R, Bossone E & Wilson S (2024) 2613 Diagnostic accuracy of the aortic dissection detection risk score alone or with D-dimer for acute aortic syndromes: systematic review and meta-analysis. RCEM Annual Scientific Conference 2024 Abstracts (pp A9.1-A9)
• Combe E, Jones D, Knight H, Laskier V, Ren K, Wright T, Boing EA & Trivedi P (2024) COMPARATIVE EFFICACY OF ELAFIBRANOR AND SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: A NETWORK META-ANALYSIS. VALUE IN HEALTH, Vol. 27(12)
• Srivastava T, Gupta A, Gautam R, Hriday K & Ren S (2024) ARE WE DEALING WITH HETEROGENEITY IN NETWORK META-ANALYSIS APPROPRIATELY? A REVIEW OF NICE SUBMISSIONS. VALUE IN HEALTH, Vol. 27(6) (pp S403-S404)
• Shah B, Challagulla S, Xu S, Williams R, Ren S, Srivastava T, Gautam R & Yang K (2024) Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 24 (pp S516-S517)
• Ren K & Forsyth J (2024) ENHANCING EXPERT ELICITATION IN HEALTH TECHNOLOGY ASSESSMENT: PRACTICAL INSIGHTS AND RECOMMENDATIONS. VALUE IN HEALTH, Vol. 27(12)
• Knowles M, Kroep S & Ren K (2024) COMPARATIVE EFFICACY OF TREATMENTS IN ADVANCED/METASTATIC PANCREATIC CANCER: DEMONSTRATING THE POWER OF MULTI-LEVEL NETWORK META REGRESSION. VALUE IN HEALTH, Vol. 27(12)
• Grand T, Thokala P, Ren K, Regnier S, Astroem OD, Awad SF, Bidani A & Krismer PF (2024) USE OF DISEASE ANALOGUES TO INFORM HEALTH-ECONOMIC PARAMETERS FOR ECONOMIC EVALUATIONS OF RARE DISEASES: A CASE-STUDY OF MULTIPLE SYSTEM ATROPHY. VALUE IN HEALTH, Vol. 27(12) (pp S120-S120)
• Forsyth J, Mitra S, Wong R, Srivastava T & Ren K (2024) CAN EXCESS HAZARD MODELS ENHANCE SURVIVAL ANALYSIS IN HEALTH TECHNOLOGY ASSESSMENTS?. VALUE IN HEALTH, Vol. 27(12) (pp S375-S375)
• Forsyth J, Wong R & Ren K (2024) ARE WE MAKING EXPERT USE OF EXPERTS? A SCOPING REVIEW OF EXPERT ELICITATION IN SURVIVAL EXTRAPOLATION. VALUE IN HEALTH, Vol. 27(12) (pp S620-S620)
• Wheat H, Ren K & Stevenson MD (2024) INVESTIGATING THE USE OF THE DIFFERENCE METHOD FOR SAMPLING MORE THAN TWO ORDERED VARIABLES. VALUE IN HEALTH, Vol. 27(12)
• Dunnewind N, Ainsworth C, Ren S & Kroep S (2023) PRIORS ON BETWEEN- STUDY HETEROGENEITY IN BAYESIAN META-ANALYSIS MODELS: A SIMULATION STUDY USING HAMILTONIAN MONTE CARLO SAMPLING. VALUE IN HEALTH, Vol. 26(12) (pp S557-S557)
• Ren S (2023) A NOVEL UNANCHORED SIMULATED TREATMENT COMPARISON APPROACH FOR TIME-TO-EVENT DATA. VALUE IN HEALTH, Vol. 26(12) (pp S424-S424)
• Sultana N & Ren S (2022) REVIEW OF METHODS USED TO ESTIMATE TREATMENT EFFECTS AGAINST RELEVANT COMPARATORS USING EVIDENCE FROM SINGLE-ARM STUDIES IN NICE SINGLE TECHNOLOGY APPRAISALS. VALUE IN HEALTH, Vol. 25(12) (pp S10-S10)
• Zhu D, Ren S, Mills K, Lemp-Hull J, Dhariwal M & Srivastava T (2022) RATE OF COMPLETE SPECTACLE INDEPENDENCE WITH A TRIFOCAL IOL: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS. VALUE IN HEALTH, Vol. 25(12) (pp S378-S378)
• Ren S, Strong M & Welton N (2022) AN EXTENDED SIMULATED TREATMENT COMPARISON APPROACH ACCOUNTING FOR UNOBSERVED CONFOUNDING IN INDIRECT COMPARISONS FOR SINGLE-ARM TRIALS. VALUE IN HEALTH, Vol. 25(12) (pp S358-S358)
• Thokala P, Stevenson M, Kumar VM, Ren S, Chapman R, Ellis A & Rind D (2019) PRO15 COST-EFFECTIVENESS OF NUSINERSEN AND ONASEMNOGENE ABEPARVOVEC FOR INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (TYPE I SMA) IN THE US. Value in Health, Vol. 22 (pp S337-S338)
• Ren S, Oakley JE & Stevens JW (2017) EVIDENCE SYNTHESIS FOR HEALTH TECHNOLOGY ASSESSMENT WITH LIMITED STUDIES. VALUE IN HEALTH, Vol. 20(9) (pp A770-A770)
• Harnan S, Ren S, Gomersall T, Everson-Hock E, Sutton A, Dhanasiri S & Kulasekararaj A (2014) Systematic Review and Meta-Analysis of the Association Between Transfusion Independence (TI) and Overall Survival (OS) in Patients (pts) with Myelodysplastic Syndromes (MDS). Blood, Vol. 124(21) (pp 1934-1934)
• Almond C, Stevens JW, Ren K & Batty A (2013) The Estimated Survival of Patients with Double Refractory Chronic Lymphocytic Leukaemia; A Reanalysis of NICE TA202 Using Bayesian Methodology to Model Observed Data. Value in Health, Vol. 16(7) (pp A397-A397)

Posters

• Zhu D, Ren S, Mills K, Lemp-Hull J, Dhariwal M & Srivastava T (2022) MT2 Rate of Complete Spectacle Independence With a Trifocal IOL: A Systematic Literature Review and Meta-Analysis.
• Ghabri S, Simpson EL, Ren S, Hock E, Archer R, Binard A, Pers Y, Stevens JW, Herpin C & Stevenson M (2018) PMS4 - RHEUMATOID ARTHRITIS TREATED WITH SIX-MONTHS OF FIRST-LINE BIOLOGIC OR BIOSIMILAR THERAPY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.
• Ren S, Oakley J & Stevens JW (2018) Evidence synthesis with limited studies. HTAi 2018, Vancouver, Canada.
• Ren S, Oakley J & Stevens JW (2017) Evidence synthesis for health technology assessment with limited studies.. . ISPOR Glasgow 2017.
• Goodacre S (2014) PRE-HOSPITAL NON-INVASIVE VENTILATION FOR ACUTE RESPIRATORY FAILURE: A SYSTEMATIC REVIEW AND NETWORK META ANALYSIS.
• Ren S, Cooper K, Cooper J, Smith H & Shaikh S A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease (2014).
• Goodacre S, Pandor A, Poku E, Stevens JW, Ren S & Cantrell A Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and network meta-analysis. 999 EMS Research Forum Conference.

Preprints

• Thokala P, Fuller GW, Goodacre S, Keating S, Herbert E, Perkins G, Rosser A, Gunson I, Miller J, Ward M , Bradburn M et al (2021) Cost-effectiveness of Out-of-Hospital Continuous Positive Airway Pressure for Acute Respiratory Failure: Decision analytic modelling using data from a feasibility trial, Research Square Platform LLC.
• Thokala P, Fuller GW, Goodacre S, Keating S, Herbert E, Perkins G, Rosser A, Gunson I, Miller J, Ward M , Bradburn M et al (2020) Cost-effectiveness of Out-of-Hospital Continuous Positive Airway Pressure for Acute Respiratory Failure: Decision analytic modelling using data from a feasibility trial, Research Square Platform LLC.
• Thokala P, Fuller GW, Keating S, Herbert E, Rosser A, Gunson I, Miller J, Ward M, Bradburn M, Marsh M & Ren K (2020) Cost-effectiveness of Out-of-Hospital Continuous Positive Airway Pressure for Acute Respiratory Failure: Decision analytic modelling using data from a feasibility trial, Research Square Platform LLC.
• Duro E, Julious PS & Ren S () An Investigation of the Constancy of Effect in Cochrane Systematic Reviews in Context with the Assumptions for Non-Inferiority trials., Research Square Platform LLC.